KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial.

Eun Joo Cho, Moo Hyun Kim, Young-Hak Kim, Kiyuk Chang, Dong-Ju Choi, Woong Chol Kang, Jinho Shin, Seong Hwan Kim, Namho Lee, Jang Won Son, Joon-Hyung Doh, Woo-Shik Kim, Soon Jun Hong, Moo-Yong Rhee, Youngkeun Ahn, Sang-Wook Lim, Seung Pyo Hong, So-Yeon Choi, Min Su Hyon, Jin-Yong Hwang, Kihwan Kwon, Kwang Soo Cha, Sang-Hyun Ihm, Jae-Hwan Lee, Byung-Su Yoo, Hyo-Soo Kim

J Clin Hypertens (Greenwich) 25(9) 817-827

PMID37614053
PMCIDPMC10497032
DOI10.1111/jch.14707
发表日期2023-08-24
入排依据:The study is a Phase III randomized trial of a drug-containing triple combination therapy, but it is for hypertension (non-oncology) and its primary efficacy endpoint is a change in blood pressure, not a time-to-event outcome like OS, PFS, DFS, etc., or Kaplan-Meier/HR analysis.
摘要

摘要

The authors evaluated the efficacy, safety, and characteristics of patients who respond well to standard dose triple combination therapy including chlorthalidone 25 mg with telmisartan 80 mg plus amlodipine 5 mg in hypertensive patients. This is a multicenter, double-blind, active-controlled, phase 3, randomized trial. Patients are randomized to triple combination (telmisartan 40 mg/amlodipine 5 mg/chlorthalidone 12.5 mg, TEL/AML/CHTD group) or dual combination (telmisartan 40 mg/amlodipine 5 mg, TEL/AML group) treatment and then dose up titration to TEL 80/AML5/CHTD25mg and TEL80/AML5, respectively. The primary endpoint is the change of mean sitting systolic blood pressure (MSSBP) at week 8. A Target BP achievement rate, a response rate, and the safety endpoints are also evaluated. Total 374 patients (mean age = 60.9 ± 10.7 years, male = 78.3%) were randomized to the study. The baseline MSSBPs/diastolic BPs were 149.9 ± 12.2/88.5 ± 10.4 mm Hg. After 8 weeks treatment, the change of MSSBPs at week 8 are -19.1 ± 14.9 mm Hg (TEL/AML/CHTD) and -11.4 ± 14.7 mm Hg (TEL/AML) (p < .0001). The achievement rates of target BP (53.8% vs. 37.8%, p = .0017) and responder rate (54.8% vs. 35.6%, p = .0001) at week 8 were significantly higher in TEL/AML/CHTD. There are no serious adverse event and no one discontinued medication due to adverse event. Among the TEL 80/AML5/CHTD25mg treatment group, patients of female or age ≥ 65 years old showed higher rate of target BP achievement than relatively young male. (61.4 vs. 46.8%, p = .042) Our study showed standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg is efficacious and safe in treatment of primary hypertension. Target BP achievement with triple therapy would be facilitated in female or old age.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。